Development of a novel prognostic model for mantle cell lymphoma based on quantitative detection of CD3 by quantitative dot blot
CD3+ T cells are an important prognostic biomarker in MCL, with high expression indicating a better prognosis. Integrating CD3 into the MIPI model enhances risk stratification accuracy. Compared to traditional IHC, QDB provides a more precise and reliable method for measuring CD3+ T cells. However, further validation in larger MCL cohorts is necessary to confirm its clinical utility. Future research should integrate immune and molecular biomarkers to further refine MCL risk models and advance personalized treatment.
Authors
- Ning Zhu (ORCID: https://orcid.org/0000-0001-7877-8179)
- Yunjun Wang
- Fangrong Tang (ORCID: https://orcid.org/0000-0003-4425-4443)
- Jiajia Hu (ORCID: https://orcid.org/0000-0002-9476-9368)
- Guohua Yu (ORCID: https://orcid.org/0000-0002-3260-3178)
- Xiaoyan Lin
- Cuijuan Zhang (ORCID: https://orcid.org/0000-0002-1268-9349)
Institutions
- Binzhou Medical University (CN)
- Shandong University of Aeronautics (CN)
- Yantai University (CN)
- Southwest Medical University (CN)
- Yuhuangding Hospital (CN)
- Shandong Provincial Hospital (CN)
- Qilu Hospital of Shandong University (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-09-10
- DOI
- https://doi.org/10.3389/fonc.2025.1595572
- Citations
- 1
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.47